JB Chemicals Acquires Several Sanzyme Brands
The $83m Transaction Is Expected To Close Within The Next Two Weeks
JB Chemicals has purchased a number of leading brands from Sanzyme, which it plans to scale up and institutionalize within India. The transaction, worth over $80m, is expected to close within the next two weeks.
You may also be interested in...
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.